Skip to main content
رجوع
CLCGY logo

Clicks Group Limited

جودة البيانات: 100%
CLCGY
OTC Healthcare Medical - Pharmaceuticals
KWD 34.69
▲ KWD 0.45 (1.31%)
القيمة السوقية: 4.09B
نطاق اليوم
KWD 34.20 KWD 34.69
نطاق 52 أسبوعًا
KWD 33.51 KWD 44.89
حجم التداول
277
متوسط 50 يوم / 200 يوم
KWD 39.52 / KWD 40.93
الإغلاق السابق
KWD 34.24

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 1.3 0.4
P/B 0.6 2.9
ROE % 48.1 3.7
Net Margin % 6.3 3.9
Rev Growth 5Y % 7.6 10.0
D/E 1.0 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2027 KWD 0.000
KWD 0.000 – KWD 0.000
56 B 0
FY2026 KWD 0.000
KWD 0.000 – KWD 0.000
52 B 0

النقاط الرئيسية

Revenue grew 7.58% annually over 5 years — modest growth
ROE of 48.10% indicates high profitability
Generating 4.15B in free cash flow
P/E of 1.30 — trading at a low valuation
PEG of 0.43 suggests growth is underpriced
Cash machine — converts 131.53% of earnings into free cash flow

النمو

Revenue Growth (5Y)
7.58%
Revenue (1Y)10.07%
Earnings (1Y)11.23%
FCF Growth (3Y)32.06%

الجودة

Return on Equity
48.10%
ROIC25.22%
Net Margin6.31%
Op. Margin9.12%

الأمان

Debt / Equity
0.98
Current Ratio1.11
Interest Coverage12.85

التقييم

P/E Ratio
1.30
P/B Ratio0.60
EV/EBITDA1.66
Dividend Yield0.02%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10.07% Revenue Growth (3Y) 9.62%
Earnings Growth (1Y) 11.23% Earnings Growth (3Y) 11.52%
Revenue Growth (5Y) 7.58% Earnings Growth (5Y) 14.47%
Profitability
Revenue (TTM) 50.01B Net Income (TTM) 3.16B
ROE 48.10% ROA 14.01%
Gross Margin 25.49% Operating Margin 9.12%
Net Margin 6.31% Free Cash Flow (TTM) 4.15B
ROIC 25.22% FCF Growth (3Y) 32.06%
Safety
Debt / Equity 0.98 Current Ratio 1.11
Interest Coverage 12.85 Dividend Yield 0.02%
Valuation
P/E Ratio 1.30 P/B Ratio 0.60
P/S Ratio 0.08 PEG Ratio 0.43
EV/EBITDA 1.66 Dividend Yield 0.02%
Market Cap 4.09B Enterprise Value 7.58B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 50.01B 45.44B 41.62B 39.59B 37.34B
Net Income 3.16B 2.84B 2.54B 2.64B 1.84B
EPS (Diluted) 39.32 23.84 20.84 21.60 14.88
Gross Profit 12.75B 10.63B 9.31B 8.43B 7.27B
Operating Income 4.56B 4.17B 3.62B 3.65B 2.90B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 22.52B 20.82B 19.03B 17.86B 17.17B
Total Liabilities 15.69B 14.53B 13.07B 12.17B 12.37B
Shareholders' Equity 6.84B 6.29B 5.96B 5.70B 4.81B
Total Debt 6.73B 3.79B 3.24B 3.10B 2.92B
Cash & Equivalents 3.25B 2.70B 2.46B 2.01B 2.21B
Current Assets 14.20B 12.89B 11.83B 11.37B 11.24B
Current Liabilities 12.77B 11.83B 10.80B 9.93B 10.20B

درجات الاستراتيجيات

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
#175 of 1024
63
#544 of 616
11
#124 of 658
52

النشاط الأخير

دخل Cash Flow Compounder
Mar 24, 2026
دخل Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
دخل Contrarian Investing (David Dreman)
Mar 24, 2026